Oura filed confidential draft IPO paperwork with the U.S. Securities and Exchange Commission, making it one of Europe's most valuable consumer health companies to pursue a Wall Street listing. The filing follows a fall 2025 funding round that valued the business at $11 billion — more than double its $5 billion valuation in 2024.
CEO Tom Hale said the company had sold more than 5.5 million rings through the third quarter of last year. At that point, Hale projected Oura would reach $2 billion in annual revenue in 2026, up from $500 million two years earlier — a fourfold increase that anchors the company's pitch to public investors.
Oura has not disclosed the number of shares it plans to offer or its expected price range, standard for a confidential S-1 submission. The confidential process, established under the JOBS Act, allows companies to test investor appetite before committing to a public filing.
The growth narrative centers on a shift from hardware to recurring software revenue. Oura is on pace to surpass 5 million paid subscribers to its health platform, which tracks sleep, heart rate, stress and recovery. Device margins are thin, but software revenue commands higher multiples in public markets.
Over the past two years, Oura expanded into AI-powered health analysis, women's health tools and personalized coaching that interprets physiological data. Those additions move Oura away from hardware competition with Apple, Garmin and Samsung toward a platform model comparable to digital health companies with software-level valuations.
Although Oura was founded in Finland and retains European research and design operations there, it reorganized under a U.S. parent company headquartered in San Francisco. That move was made explicitly to access American venture capital. The SEC filing follows from that structure — listing in the United States was the endpoint the company built toward when it redomiciled.
Oura is not alone. The Finnish company joins a lengthening list of European-founded technology businesses that have chosen U.S. exchanges over European alternatives. The same week Oura's filing emerged, Aggreko — a U.K.-based power equipment rental company — filed for a NYSE IPO under the ticker AGKO. Two high-profile filings from European firms targeting U.S. markets in the same week sharpens the debate over whether European exchanges have a structural disadvantage in retaining homegrown companies.
The counterargument is that Oura's move reflects its specific investor base rather than a verdict on European markets broadly. The company raised capital from U.S. venture funds and built executive leadership in San Francisco. A U.S. listing is the natural exit for that capital stack regardless of where the product was invented.
That argument, however, does not fully account for why European founders increasingly choose the U.S. capital path from earliest stages. Oura's trajectory — Finnish origin, U.S. redomiciliation, SEC filing — is now a well-worn template. The 2025 funding round that pushed valuation to $11 billion attracted capital that expects a Nasdaq or NYSE exit.
The IPO timeline depends on SEC review and market conditions. Oura has not set a listing date. The Nasdaq composite fell 0.8 percent on Aug. 25, while the S&P 500 dropped 0.3 percent. Public market pricing will be set against Oura's 2026 revenue trajectory and the multiple investors are willing to pay for a health platform at that growth rate.
